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Solving	the	molecular	structure	of	hybrid	human-porcine factor	VIII	
through	X-ray	crystallization
Mikko	Sayre,	Amanda	Weis,	Brenna	Park-Egan,	and	Paul	C.	Spiegel
Department	of	Chemistry,	Western	Washington	University,	Bellingham,	WA
Abstract:
Factor	VIII	(fVIII)	is	a	protein	that	is	involved	in	the	coagulation	cascade,	a	
collection	of	reactions	that	is	activated	by	injury	and	leads	to	the	
formation	of	blood	clots.	Deficiencies	in	fVIII	lead	to	the	bleeding	
disorder	hemophilia	A,	a	condition	that	occurs	in	1	in	5000	births.	The	
current	treatment	for	hemophilia	A	is	inefficient	and	costly;	however,	
there	is	potential	through	the	use	of	recombinant	hybrid	human-porcine	
fVIII.	Hybrid	fVIII	shows	up	to	12-fold	higher	coagulant	activity	than	
human	fVIII,	and	can	retain	its	activity	even	in	the	presence	of	inhibitory	
antibodies.	The	primary	objective	of	our	study	is	to	determine	the	
molecular	structure	of	full-length	hybrid	human-porcine	fVIII	through	X-
ray	crystallography.	This	allows	us	to	see	how	the	protein	functions	on	a	
molecular	level,	along	with	the	details	of	its	interactions	with	binding	
partners.	Thus	far	we	have	produced	crystals	of	fVIII	in	complex	with	IgG	
antibodies	3E6	FAB and	G99	FAB,	along	with	the	TIL’E’	domain	of	binding	
partner	von	Willebrand factor.	These	crystals	have	exhibited	limited	
diffraction,	and	we	are	working	towards	optimizing	crystals	to	increase	
the	resolution	of	the	diffraction	pattern.	The	structure	of	hybrid	fVIII	has	
not	yet	been	studied	in	detail,	and	this	information	could	demonstrate	
the	its	viability,	bringing	us	one	step	closer	to	a	long-term,	effective,	and	
economical	treatment	of	hemophilia.
Figure	2.	Schematic	of	the	light-chain	subunit	
of	fVIII	with	TIL’E’	and	IgG	antibodies	G99	FAB
and	3E6	FAB bound.
Methods:
Hybrid	fVIII	expression	and	
preparation:
• Hybrid	fVIII	was	prepared	by	Dr.	
Lollar’s lab	at	Emory	University
• To	increase	expression,	the	B-
domain	was	removed	and	porcine	
sequences	were	added	to	the	A1	
and	ap-A3	domain	(Figure	3).6
• To	decrease	immune	response,	
porcine	sequences	were	added	to	
the	C1	domain	and	substitutions	
were	made	in	A2	(Figure	3).6
• fVIII	complex	consists	of	hybrid	fVIII	
bound	to	combinations	of	
antibodies	(3E6	FAB and/or	G99	FAB)	
along	with	the	TIL’E’	domain	of	the	
D’D3	subunit	of	vWF (Figure	2).
Background:	fVIII	and	Hemophilia	A
Figure	1.	The	Coagulation	Cascade.1 When	tissue	damage	occurs,	the	intrinsic	
pathway	of	the	coagulation	cascade	is	activated.	fVIII	circulates	in	its	inactive	form	
bound	to	vWF.	Upon	activation,	vWF is	cleaved	and	fVIIIa acts	as	a	cofactor	for	fIX.	
• fVIII	is	a	heterodimer	made	up	of	a	heavy	chain	(with	domains	A1-
A2-B)	and	a	light	chain	(A3-C1-C2).2
• Individuals	with	hemophilia	A	have	little	or	no	ability	to	produce	
fVIII,	and	as	a	result	cannot	form	clots.
• About	one	half	of	diagnosed	hemophilia	A	patients	have	the	
severe	form	of	the	disease,	with	less	than	1%	of	normal	fVIII.3
• Treatment	for	hemophilia	averages	$468,000	per	year.4
• Recently,	potential	has	been	shown	through	the	use	of	hybrid	
human-porcine	fVIII.5
• Hybrid	fVIII	shows	up	to	12-fold	higher	coagulation	activity	than	
human	fVIII,	and	retains	activity	in	presence	of	inhibitory	
antibodies	that	affect	human	fVIII.5
• The	structure	of	hybrid	fVIII	has	not	yet	been	studied	in	detail.
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Results	and	Future	Work:
• Hybrid	fVIII	+	G99	FAB crystals	have	
diffracted	to	a	resolution	of	4-8	Å
(Figure	4a,b).
• Crystals	of	fVIII	complex	with	various	
binding	partners	have	been	
produced	in	several	conditions.
• Current	goals	include	modulation	of	
conditions	to	produce	crystals	of	
fVIII+TIL’E’+3E6	FAB and	fVIII+TIL’E’+	
G99	FAB.
• The	ultimate	goal	is	to	obtain	
diffraction	results	with	a	resolution	
of	1-3	Å.
Figure	4.	Hybrid	fVIII	complex	
crystallization	results.	a)	fVIII+G99	FAB in	
0.050	M	DL-Malic	acid	pH	7.0,	12%	PEG	
3350.	b)	fVIII+G99	FAB in	0.050	M	DL-Malic	
acid	pH	6.8,	10%	PEG	3350 c)
fVIII+TIL’E’+3E6	FAB in	0.1	M	BIS-TRIS	
propane	pH	8.0,	32%	PEG	6000.	d)	
fVIII+TIL’E’+G99	FAB in	0.1	M	MES	
monohydrate	pH	6.0,	22%	PEG	400	
a b
c d
X-ray	Crystallography:
• Crystals	are	produced	through	hanging	drop	vapor	diffusion	(Figure	4).
• Successful	crystallization	involves	extensive	modulation	of	buffers,	ionic	
strengths,	and	precipitants.
Figure	4.	The	hanging-drop	
vapor	diffusion	
crystallization	method.
Figure	3.	Hybrid	fVIII	gene	construct.6 The	B-
domain	of	human	fVIII	was	removed,	and	
porcine	sequences	were	inserted	(shown	in	
yellow).
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